Humacyte Presents In Vivo Data on Biovascular Pancreas Transplantation for Type 1 Diabetes Treatment
DURHAM, N.C., June 08, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today presented initial data from laboratory and preclinical models demonstrating the potential to engineer a biovascular pancreas to deliver islet cells to produce insulin in Type 1 diabetic patients.
The data show that pancreatic islet cells embedded in the outer matrix of an acellular vessel can create a biovascular pancreas transplant. In preclinical models, the islets on the surface of the biovascular pancreas sensed blood glucose and delivered insulin to the animal subjects, in therapeutic quantities. In addition to glucose sensing and insulin delivery, the biovascular pancreas supported islet graft oxygenation and vascularization, reducing islet hypoxia and cell death as compared to control, non-vascular implants which displayed islet death and did not correct blood glucose levels.
“These data demonstrate the potential to engineer a biovascular pancreas based on our HAV platform technology, that may effectively deliver islet cells that can produce insulin for people with Type 1 diabetes. Type 1 diabetics no longer make their own insulin, and currently face limited curative treatment options including pancreas transplant, which is a morbid procedure. Without transplantation, Type 1 diabetics are committed to life-long insulin use,” said Jeffrey Lawson, M.D., Ph.D., Chief Surgical Officer of Humacyte. “Our approach to leverage the HAV to deliver islet cells may overcome major challenges faced by transplantation of islets, including ensuring islets receive adequate oxygen. We’re encouraged by these data and look forward to continuing to evaluate the HAV for therapeutic cell transplantation.”
The data were presented June 6 by Dr. Lawson at the American Transplant Congress 2021 Virtual Connect and will be available on Humacyte.com.
Dr. Lawson’s Congress presentation also highlighted cumulative HAV clinical data. To date, there have been no instances of clinical HAV rejection observed in more than 430 evaluated patients. Remodeling of the HAV with host cells, in samples taken from patients to date, has been consistent. Further, the HAV has shown no evidence of stimulation of significant adaptive immunity.
On February 17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement.
About Alpha Healthcare Acquisition Corp.
Important Information About the Merger and Where to Find It
Participants in the Solicitation
Humacyte Investor Contact: